Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-27
2008-05-27
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S256000, C544S279000, C544S117000, C514S236200, C514S234200
Reexamination Certificate
active
07378423
ABSTRACT:
The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I]wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist.
REFERENCES:
patent: 2004/0138285 (2004-07-01), Okazaki
patent: 2 385 412 (2002-11-01), None
patent: 2002-532414 (2002-10-01), None
patent: 2002-532415 (2002-10-01), None
patent: 2002-534380 (2002-10-01), None
patent: 2002-534381 (2002-10-01), None
patent: 2002-332247 (2002-11-01), None
patent: 2003-504401 (2003-02-01), None
patent: 2004-504294 (2004-02-01), None
patent: WO 00/35435 (2000-06-01), None
patent: WO 00/35436 (2000-06-01), None
patent: WO 00/40235 (2000-07-01), None
patent: WO 00/40237 (2000-07-01), None
patent: WO 01/05393 (2001-01-01), None
patent: WO 02/03997 (2002-01-01), None
patent: WO 02/06213 (2002-01-01), None
patent: WO 02/06520 (2002-01-01), None
patent: WO 02/087620 (2002-11-01), None
patent: WO 02/094824 (2002-11-01), None
patent: WO 03/062236 (2003-07-01), None
Calvet, J. Am. Soc. Nephrol, 17: 1498-1500, 2006.
Guo, et al., Leukemia, 2006, 20, pp. 115-121.
Boultwood, et al., Brit. J. of Haematol, 138, pp. 3-11, 2007.
Wang, et al., J. Biol. Chem., vol. 280, No. 13, 2005, pp. 12339-12343.
Tamir, et al., Cell Growth & Differentiation, vol. 11, pp. 269-277, May 2000.
Crees, Calif. St. J. Med., vol. V, No. II, 1907, pp. 292-293.
Burova et al.,Chemistry of Heterocyclic Compounds, 5: 674-680 (1991) [Translation pp. 538-544 (1991)].
Hannon et al.,Nature, 371: 257-261 (Sep. 15, 1994).
Hitomi et al.,FEBS Letters, 554: 347-350 (2003).
Hoshino et al.,Journal of Biological Chemistry, 276(4): 2686-2692 (Jan. 26, 2001).
Khattab et al.,Journal für Praktische Chemie, 338: 151-156 (1996).
Ogura et al.,Chem. Pharm. Bull., 21(9): 2014-2018 (1973).
Su et al.,Journal of Medicinal Chemistry, 29(5): 709-715 (1986).
Abe Hiroyuki
Hayakawa Kazuhide
Hori Yoshikazu
Iida Tetsuya
Kawasaki Hisashi
Berch Mark L.
Jaisle Cecilia M
Japan Tobacco Inc.
Leydig , Voit & Mayer, Ltd.
LandOfFree
Pyrimidine compound and medical use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine compound and medical use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine compound and medical use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2766591